Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity
· resalis therapeutics srl
Source Summary
Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide targeting microRNA-22 (miR-22), designed to address the underlying drivers of obesity by targeting metabolic dysfunction to deliver durable, fat-selective weight loss with lean mass preservation. The study will investigate the effect of RES-010 on body weight loss and other weight loss-related parameters, and evaluate safety, tolerability, and pharmacokinetics during 3 months of treatment in overweight and obese participants. The clinical study will be conducted at a single site in Australia, with topline data expected in late 2026.